Summary
Dr. Jun Ishihara is a Lecturer (US equivalent: assistant professor) in the Department of Bioengineering at Imperial College London. The Ishihara laboratory works in the field of protein engineering, with research foci in cancer immunotherapy, autoimmunity, and regenerative medicine.
Dr. Ishihara received his PhD in stem cell biology from the University of Tokyo. He then conducted postdoctoral training in the laboratory of Jeffrey Hubbell first at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland from 2014 to 2016 and then at the University of Chicago from 2016 to 2020 when the laboratory relocated to the Pritzker School of Molecular Engineering.
Dr. Ishihara has developed novel technologies in the field of immuno-engineering in order to improve current therapies and discover new drugs. He has developed novel approaches to cancer immunotherapy that achieve localised immune activation by targeting the tumour microenvironment. These methods make cancer immunotherapy safe and effective. Dr. Ishihara has also engineered treatments for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In the field of regenerative medicine, he has developed novel approaches to efficiently deliver growth factors to the wound site to promote wound healing.
Dr. Ishihara has co-authored 25 scientific papers and 16 patents, with publications in Nature Biomedical Engineering, Science Translational Medicine, Science Advances, Blood and Nature Communications. He is also a co-founder of Arrow Immune Inc., focusing on clinical translation of cancer immunotherapy techniques, HeioThera Inc., focusing on clinical translation of anti-inflammatory the therapeutics, and ScienceLounge LLC., which runs a science bar in Tokyo for scientific outreach activities.
Dr. Ishihara's research publications can be found on Google Scholar https://scholar.google.com/citations?user=lAoKMNgAAAAJ&hl=en
Publications
Journals
Bhatia V, Kamat NV, Pariva TE, et al., 2023, Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy., Nat Commun, Vol:14
Mansurov A, Hosseinchi P, Chang K, et al., 2022, Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker, Nature Biomedical Engineering, Vol:6, ISSN:2157-846X
Ishihara A, Ishihara J, Watkins EA, et al., 2021, Prolonged residence of an albumin–IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis, Nature Biomedical Engineering, Vol:5, ISSN:2157-846X, Pages:387-398
Yuba E, Budina E, Katsumata K, et al., 2021, Enhanced lymph node trafficking of engineered IL‐10 suppresses rheumatoid arthritis in murine models, Arthritis & Rheumatology, Vol:73, ISSN:2326-5191, Pages:769-778
Mansurov A, Ishihara J, Hosseinchi P, et al., 2020, Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours, Nature Biomedical Engineering, Vol:4, ISSN:2157-846X, Pages:531-543